Collection of Biological Samples With Clinical Characterization of Covid-19 Patients

Study Overview
=================
Brief Summary
-----------------
Biological collection (blood sample) associated with clinical data from Covid-19 patients

Detailed Description
-----------------
SARS-Cov2 is an emerging respiratory virus in the coronavirus family, responsible of the pandemic since November 2019. France, which has more than 17,000 deaths from the virus, is one of the main outbreaks. As of 16 April 2020, more than 76,000 individuals in France have been hospitalized, corresponding to 69% of confirmed cases (https://www.santepubliquefrance.fr). Most affected patients have more or less marked clinical signs associating fever, cough, dyspnea, myalgia, anosmia, ageusia, digestive disorders. In some cases, the progression is worse with lung disease of varying severity. Indications for hospitalization are essentially the severe forms of Covid-19 disease, characterized by hypoxemic lung disease. Risk factors for developing severe Covid-19 disease have been identified already: age, co-morbidity such as diabetes, obesity-overweight or cardiovascular diseases. It is assumed that other host-related factors, including genetics, may contribute to the existence of this phenotypic heterogeneity. At present, these factors are not known. The objective of this research is to constitute a DNA collection from patients with Covid-19, in order to be able to search for genetic factors modulating the clinical phenotype.

Official Title
-----------------
Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization

Conditions
-----------------
Covid-19

Intervention / Treatment
-----------------
* Biological: Biological test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of COVID-19 confirmed on RT-PCR test or chest scanner Any age Membership in the general social security system Inform consent signed by the patient or by legal representatives for minors Exclusion Criteria: Refusal of the patient or one of the legal representatives
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Collection of blood samples in a cohort of Covid-19 patients
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Collection of blood sample<br> | Biological: Biological test<br>* Blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phenotype/genotype correlation research modulating the severity of Covid-19 disease | Clinical aggravation markers (admission in intensive care) | Anytime in the period of 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease | Severity at the Covid-19 Lung Scanner | Anytime in the period of 10 years | 
| Phenotype/biomarker correlation research modulating the severity of Covid-19 disease | Severity at the Covid-19 Lung Scanner | Anytime in the period of 10 years | 
| Development of clinical-biological scores in the severity of Covid-19 disease | Evolution of scanographic lesions or pulmonary ultrasound | Anytime in the period of 10 years | 
| Development of predictive imaging scores in the severity of Covid-19 disease | Evolution of scanographic lesions or pulmonary ultrasound | Anytime in the period of 10 years | 
| Identification of pathophysiological pathways to susceptibility to Covid-19 disease | Duration of oxygen therapy, artificial ventilation | Anytime in the period of 10 years | 
| Identification of genetic markers for treatment response | Genome sequencing | Anytime in the period of 10 years | 
| Identification of transcriptomic markers for treatment response | Sequencing transcriptome | Anytime in the period of 10 years | 
| Identification of proteomic for treatment response | Proteomic sequencing | Anytime in the period of 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood samples, ADN, ARN, plasma